Search CTL/CD8+ T-Cell Epitope Database

Found 56 matching records:

Displaying record number 61798

Download this epitope record as JSON.

HXB2 Location	Gag(426-436) p2p7p1p6(63-73) DNA(2065..2097)	Gag Epitope Map
Author Location
Epitope	`CTERQANFLGK`	Epitope Alignment
Epitope Name	CK11
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID421: A02:01, A11:01, B35:03, B40:02, C02:02, C12:03
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, optimal epitope, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope CTERQANFLGK (TK10) is within peptide CTERQANFLGKIWPS (HC031) that was recognized by VID421, 1/12 vaccinated subjects, and previously reported to mediate high HIV-1 inhibitory activity. It is one of 3 truncated peptides within HC031 that elicit equally strong CTL response as seen by ICS. Authors predict restricting HLA to be A*1101.

References

Borthwick2017 Nicola Borthwick, Zhansong Lin, Tomohiro Akahoshi, Anuska Llano, Sandra Silva-Arrieta, Tina Ahmed, Lucy Dorrell, Christian Brander, Hayato Murakoshi, Masafumi Takiguchi, and Tomáš Hanke. Novel, In-Natural-Infection Subdominant HIV-1 CD8+ T-Cell Epitopes Revealed in Human Recipients of Conserved-Region T-Cell Vaccines. PLoS One, 12(4):1-19, 2017. PubMed ID: 28448594. Show all entries for this paper.

Displaying record number 61733

Download this epitope record as JSON.

HXB2 Location	Gag(426-440) p2p7p1p6(63-77) DNA(2065..2109)	Gag Epitope Map
Author Location	p2p7p1p6(63-77)
Epitope	`CTERQANFLGKIWPS`	Epitope Alignment
Epitope Name	HC031
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID421: A02:01, A11:01, B35:03, B40:02, C02:02, C12:03
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Peptide HC031, CTERQANFLGKIWPS, was recognized by VID421, 1/12 vaccinated subjects, and previously reported to mediate high HIV-1 inhibitory activity. It contains 3 truncated peptides eliciting equally strong CTL response as seen by ICS: TERQANFL, TERQANFLGK, CTERQANFLGK.

References

Displaying record number 61796

Download this epitope record as JSON.

HXB2 Location	Gag(427-434) p2p7p1p6(64-71) DNA(2068..2091)	Gag Epitope Map
Author Location
Epitope	`TERQANFL`	Epitope Alignment
Epitope Name	TL8
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID421: A02:01, A11:01, B35:03, B40:02, C02:02, C12:03
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, optimal epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope TERQANFL (TL8) is within peptide CTERQANFLGKIWPS (HC031) that was recognized by VID421, 1/12 vaccinated subjects, and previously reported to mediate high HIV-1 inhibitory activity. It is one of 3 truncated peptides from HC031 that elicits equally strong CTL response as seen by ICS. TL8 restricted by HLA-B*4002 is an A-list epitope in the Los Alamos HIV Immunology database (Sabbaj2003 and Zhai2008).

References

Displaying record number 61797

Download this epitope record as JSON.

HXB2 Location	Gag(427-436) p2p7p1p6(64-73) DNA(2068..2097)	Gag Epitope Map
Author Location
Epitope	`TERQANFLGK`	Epitope Alignment
Epitope Name	TK10
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID421: A02:01, A11:01, B35:03, B40:02, C02:02, C12:03
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, optimal epitope, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope TERQANFLGK (TK10) is within peptide CTERQANFLGKIWPS (HC031) that was recognized by VID421, 1/12 vaccinated subjects, and previously reported to mediate high HIV-1 inhibitory activity. It is one of 3 truncated peptides within HC031 that elicit equally strong CTL response as seen by ICS.

References

Displaying record number 61799

Download this epitope record as JSON.

HXB2 Location	Pol(153-168) Protease(97)-RT(13) DNA(2541..2588)	Pol Epitope Map
Author Location	Pol(153-168)
Epitope	`KNFPISPIETVPVKLK`	Epitope Alignment
Epitope Name	HC049
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID406: A03:01, A31:01, B40:01, B44:03, C03:04, C04:01, DQB102, DQB105, DRB101:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Peptide HC049, KNFPISPIETVPVKLK, was recognized by VID406, 1/12 vaccinated subjects, and mapping identified the B*4001-restricted A-list peptide IETVPVKL (IL8) as the optimal epitope.

References

Displaying record number 61800

Download this epitope record as JSON.

HXB2 Location	Pol(158-172) RT(3-17) DNA(2556..2600)	Pol Epitope Map
Author Location	RT(3-17)
Epitope	`SPIETVPVKLKPGMD`	Epitope Alignment
Epitope Name	HC050
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID406: A03:01, A31:01, B40:01, B44:03, C03:04, C04:01, DQB102, DQB105, DRB101:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Peptide HC050,SPIETVPVKLKPGMD, was recognized by VID406, 1/12 vaccinated subjects, and mapping identified the B*4001-restricted A-list peptide IETVPVKL (IL8) as the optimal epitope.

References

Displaying record number 61801

Download this epitope record as JSON.

HXB2 Location	Pol(160-167) RT(5-12) DNA(2562..2585)	Pol Epitope Map
Author Location
Epitope	`IETVPVKL`	Epitope Alignment
Epitope Name	IL8
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID406: A03:01, A31:01, B40:01, B44:03, C03:04, C04:01, DQB102, DQB105, DRB101:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, optimal epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope IETVPVKL (IL8) is within peptides KNFPISPIETVPVKLK (HC049) and SPIETVPVKLKPGMD (HC050) that was recognized by VID406, 1/12 vaccinated subjects. IL8 was previously reported to be an HLA-B*4001 restricted A-list epitope in the Los Alamos HIV Immunology database (Draenert2006 and Zhai2008).

References

Displaying record number 61802

Download this epitope record as JSON.

HXB2 Location	Pol(270-284) RT(115-129) DNA(2892..2936)	Pol Epitope Map
Author Location	RT(115-129)
Epitope	`YFSVPLDEGFRKYTA`	Epitope Alignment
Epitope Name	HC078
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID421: A02:01, A11:01, B35:03, B40:02, C02:02, C12:03
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Peptide YFSVPLDEGFRKYTA was recognized by VID421 and VID417, 2/12 vaccinated subjects. It contains 4 truncated peptides eliciting CTL responses as seen by ICS: SVPLDEGFRK (SK10), VPLDEGFRK (VK9), PLDEGFRKY (PY9) and VPLDEGFRKY (VY10).
VID421 responded to overlapping epitopes, HLA-A*1101-restricted SK10, and HLA-Cw*1203-restricted VK9.
VID417 responded strongly to HLA-B*3501-restricted PY9, but the optimal epitope was the longer, B*3501-restricted VY10.

References

Displaying record number 61804

Download this epitope record as JSON.

HXB2 Location	Pol(272-281) RT(117-126) DNA(2898..2927)	Pol Epitope Map
Author Location
Epitope	`SVPLDEGFRK`	Epitope Alignment
Epitope Name	SK10
Species (MHC/HLA)	human(A*11:01)
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID421: A02:01, A11:01, B35:03, B40:02, C02:02, C12:03
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, optimal epitope, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope SVPLDEGFRK (SK10) is within peptide YFSVPLDEGFRKYTA (HC078) that was recognized by VID421, 1/12 vaccinated subjects. SK10 was previously reported to be an HLA-A*11 restricted epitope but is now shown to be restricted by HLA-A*1101, and thus an A-list candidate for the Los Alamos HIV Immunology database. A variant, SVPLDEsFRK, was reported in HIV-1 exposed uninfected sex workers from Thailand (Sriwanthana2001).

References

Displaying record number 61805

Download this epitope record as JSON.

HXB2 Location	Pol(273-281) RT(118-126) DNA(2901..2927)	Pol Epitope Map
Author Location
Epitope	`VPLDEGFRK`	Epitope Alignment
Epitope Name	VK9
Species (MHC/HLA)	human(C*12:03)
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID421: A02:01, A11:01, B35:03, B40:02, C02:02, C12:03
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, optimal epitope, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope VPLDEGFRK (VK9) is within peptide YFSVPLDEGFRKYTA (HC078) that was recognized by VID421, 1/12 vaccinated subjects. VK9 is novel and restricted by HLA-Cw*1203 though it can be weakly presented by A*1101. Thus it is an A-list candidate for the Los Alamos HIV Immunology database.

References

Displaying record number 61807

Download this epitope record as JSON.

HXB2 Location	Pol(273-282) RT(118-127) DNA(2901..2930)	Pol Epitope Map
Author Location
Epitope	`VPLDEGFRKY`	Epitope Alignment
Epitope Name	VY10
Species (MHC/HLA)	human(B*35:01)
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID417: A03:01, A30:04, B35:01, B50:01, C04:01, C06:02, DQB102, DQB105, DRB101:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, optimal epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope VPLDEGFRKY (VY10) is within peptide YFSVPLDEGFRKYTA (HC078) and was recognized by VID417, 1/12 vaccinated subjects. VY10 is an optimal epitope and is known to be restricted by HLA-B*3501 as curated in the Los Alamos HIV Immunology database A-list of epitopes.

References

Displaying record number 61806

Download this epitope record as JSON.

HXB2 Location	Pol(274-282) RT(119-127) DNA(2904..2930)	Pol Epitope Map
Author Location
Epitope	`PLDEGFRKY`	Epitope Alignment
Epitope Name	PY9
Species (MHC/HLA)	human(B*35:01)
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID417: A03:01, A30:04, B35:01, B50:01, C04:01, C06:02, DQB102, DQB105, DRB101:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope PLDEGFRKY (PY9) is within peptides YFSVPLDEGFRKYTA (HC078) and PLDEGFRKYTAFTIP (HC079) that was recognized by VID417, 1/12 vaccinated subjects. PY9 is sub-optimal and is restricted by HLA-B*3501.

References

Displaying record number 61803

Download this epitope record as JSON.

HXB2 Location	Pol(274-288) RT(119-133) DNA(2904..2948)	Pol Epitope Map
Author Location	RT(119-133)
Epitope	`PLDEGFRKYTAFTIP`	Epitope Alignment
Epitope Name	HC079
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID417: A03:01, A30:04, B35:01, B50:01, C04:01, C06:02, DQB102, DQB105, DRB101:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Peptide HC079, PLDEGFRKYTAFTIP, was recognized by VID417, 1/12 vaccinated subjects. It contains a truncated peptide eliciting CTL responses as seen by ICS: PLDEGFRKY (PY9) and the optimal epitope VPLDEGFRKY (VY10).
VID417 responded strongly to HLA-B*3501-restricted PY9, but the optimal epitope was the longer, B*3501-restricted VY10 not fully contained in HC079.
VID417 responded strongly to HLA-B*3501-restricted PY9, but the optimal epitope was the longer, B*3501-restricted VY10.

References

Displaying record number 61808

Download this epitope record as JSON.

HXB2 Location	Pol(278-292) RT(123-137) DNA(2916..2960)	Pol Epitope Map
Author Location	RT(123-137)
Epitope	`GFRKYTAFTIPSINN`	Epitope Alignment
Epitope Name	HC080
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID411: A02:01, B08:01, B51:01, C03:03, C07:01, DQB102, DQB103:03, DRB103:01, DRB1*09:01, DRB3, DRB5
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Peptide HC080, GFRKYTAFTIPSINN, was recognized by VID411, 1/12 vaccinated subjectsy. It contains 3 truncated peptides eliciting equally strong CTL response as seen by ICS: TAFTIPSI, YTAFTIPSI, KYTAFTIPSI but restricted respectively by HLAs B*5101 or A*0201, A*02, and Cw*0701.

References

Displaying record number 61811

Download this epitope record as JSON.

HXB2 Location	Pol(281-290) RT(126-135) DNA(2925..2954)	Pol Epitope Map
Author Location
Epitope	`KYTAFTIPSI`	Epitope Alignment
Epitope Name	KI10
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID411: A02:01, B08:01, B51:01, C03:03, C07:01, DQB102, DQB103:03, DRB103:01, DRB1*09:01, DRB3, DRB5
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope KYTAFTIPSI (KI10) is within peptide GFRKYTAFTIPSINN (HC080) that was recognized by VID411, 1/12 vaccinated subjects. KI10 is predicted to be restricted by HLA-Cw*0701.

References

Displaying record number 61810

Download this epitope record as JSON.

HXB2 Location	Pol(282-290) RT(127-135) DNA(2928..2954)	Pol Epitope Map
Author Location
Epitope	`YTAFTIPSI`	Epitope Alignment
Epitope Name	YI9
Species (MHC/HLA)	human(A*02)
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID415: A02:01, A03:01, B07:02, B44:02, C07:02, DQB103:01, DQB106:02, DRB111:04, DRB115:01, DRB3, DRB5; VID411: A02:01, B08:01, B51:01, C03:03, C07:01, DQB102, DQB103:03, DRB103:01, DRB109:01, DRB3, DRB5
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope YTAFTIPSI (YI9) is within peptide GFRKYTAFTIPSINN (HC080) that was recognized by VID411, 1/12 vaccinated subjects. YI9 is reported as being restricted by HLA-A*02 and was seen in vaccine recipients of another study, the STEP study.
YI9 is also found within HC081, YTAFTIPSINNETPG, where it is restricted by HLA-A*0201 and elicits a weak response in VID415. A C-terminal variant of this epitope, YTAFTIPSv has previously been described.

References

Displaying record number 61812

Download this epitope record as JSON.

HXB2 Location	Pol(282-296) RT(127-141) DNA(2928..2972)	Pol Epitope Map
Author Location	RT(127-141)
Epitope	`YTAFTIPSINNETPG`	Epitope Alignment
Epitope Name	HC081
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID415: A02:01, A03:01, B07:02, B44:02, C07:02, DQB103:01, DQB106:02, DRB111:04, DRB1*15:01, DRB3, DRB5
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Peptide HC081, YTAFTIPSINNETPG, was recognized by VID415, 1/12 vaccinated subjects. It contains 3 truncated peptides eliciting CTL responses as seen by ICS: TIPSINNETPG, PSINNETPG, YTAFTIPSI.
Epitope TIPSINNETPG (TG11) within peptide YTAFTIPSINNETPG (HC081) gave the strongest immune response of all truncated peptides but is an unlikely canditdate for an epitope due to the undesirable amino acids at its C-terminus.

References

Displaying record number 61809

Download this epitope record as JSON.

HXB2 Location	Pol(283-290) RT(128-135) DNA(2931..2954)	Pol Epitope Map
Author Location
Epitope	`TAFTIPSI`	Epitope Alignment
Epitope Name	TI8
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID411: A02:01, B08:01, B51:01, C03:03, C07:01, DQB102, DQB103:03, DRB103:01, DRB1*09:01, DRB3, DRB5
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope TAFTIPSI (TI8) is within peptide GFRKYTAFTIPSINN (HC080) that was recognized by VID411, 1/12 vaccinated subjects. TI8 is probably restricted via HLAs B*5101 or A*0201.

References

Displaying record number 61813

Download this epitope record as JSON.

HXB2 Location	Pol(288-296) RT(133-141) DNA(2946..2972)	Pol Epitope Map
Author Location
Epitope	`PSINNETPG`	Epitope Alignment
Epitope Name	PG9
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID415: A02:01, A03:01, B07:02, B44:02, C07:02, DQB103:01, DQB106:02, DRB111:04, DRB1*15:01, DRB3, DRB5
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope PSINNETPG (PG9) is within peptide YTAFTIPSINNETPG (HC081) that was recognized by VID415, 1/12 vaccinated subjects. PG9 restriction was not possible, but a variant epitope, IPStNNETPG has previously been reported as a conserved HLA-B*07-restricted Pol epitope (DeGroot2008).

References

Displaying record number 61814

Download this epitope record as JSON.

HXB2 Location	Pol(310-324) RT(155-169) DNA(3012..3056)	Pol Epitope Map
Author Location	RT(155-169)
Epitope	`GSPAIFQSSMTKILE`	Epitope Alignment
Epitope Name	HC088
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID409: A01:01, A03:01, B07:02, B08:01, C07:01, C07:02, DQB102, DQB106:02, DRB103:01, DRB115:01, DRB3, DRB5; VID421: A02:01, A11:01, B35:03, B40:02, C02:02, C12:03
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Peptide HC088, GSPAIFQSSMTKILE, was recognized by VID409 and VID421, 2/12 vaccinated subjects. It contains 3 truncated peptides eliciting CTL responses as seen by ICS: SPAIFQSSMTK (SK11) restricted by HLA-B*0702 in VID409 (record #61815) as well as restricted by HLA-A*1101 in VID421 (record #61816) ; IFQSSMTKIL (IL10), (record #61817) whose restriction was not determined; and AIFQSSMTK (AK9), (record #61818) restricted by HLA-A*1101.

References

Displaying record number 61816

Download this epitope record as JSON.

HXB2 Location	Pol(311-321) RT(156-166) DNA(3015..3047)	Pol Epitope Map
Author Location
Epitope	`SPAIFQSSMTK`	Epitope Alignment
Epitope Name	SK11
Species (MHC/HLA)	human(A*11:01)
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID421: A02:01, A11:01, B35:03, B40:02, C02:02, C12:03
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, optimal epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope SPAIFQSSMTK (SK11) is within peptide GSPAIFQSSMTKILE (HC088) that was recognized by VID421, 1/12 vaccinated subjects. SK11 is restricted by HLA-A*1101 in this subject and this has only been reported as A*11 before, making it an A-list candidate for the Los Alamos HIV Immunology database.

References

Displaying record number 61815

Download this epitope record as JSON.

HXB2 Location	Pol(311-321) RT(156-166) DNA(3015..3047)	Pol Epitope Map
Author Location
Epitope	`SPAIFQSSMTK`	Epitope Alignment
Epitope Name	SK11
Species (MHC/HLA)	human(B*07:02)
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID409: A01:01, A03:01, B07:02, B08:01, C07:01, C07:02, DQB102, DQB106:02, DRB103:01, DRB115:01, DRB3, DRB5
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, optimal epitope, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope SPAIFQSSMTK (SK11) is within peptide GSPAIFQSSMTKILE (HC088) that was recognized by VID409, 1/12 vaccinated subjects. SK11 is restricted by HLA-B*0702 in this subject and this has not been reported before, making it an A-list candidate for the Los Alamos HIV Immunology database.

References

Displaying record number 61818

Download this epitope record as JSON.

HXB2 Location	Pol(313-321) RT(158-166) DNA(3021..3047)	Pol Epitope Map
Author Location
Epitope	`AIFQSSMTK`	Epitope Alignment
Epitope Name	AK9
Species (MHC/HLA)	human(A*11:01)
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID421: A02:01, A11:01, B35:03, B40:02, C02:02, C12:03
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, optimal epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope AIFQSSMTK (AK9) is within peptide GSPAIFQSSMTKILE (HC088) that was recognized by VID421, 1/12 vaccinated subjects. AK9 is restricted by HLA-A*1101 in this subject is an A-list epitope in the Los Alamos HIV Immunology database.

References

Displaying record number 61817

Download this epitope record as JSON.

HXB2 Location	Pol(314-323) RT(159-168) DNA(3024..3053)	Pol Epitope Map
Author Location
Epitope	`IFQSSMTKIL`	Epitope Alignment
Epitope Name	IL10
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID409: A01:01, A03:01, B07:02, B08:01, C07:01, C07:02, DQB102, DQB106:02, DRB103:01, DRB115:01, DRB3, DRB5
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope IFQSSMTKIL (IL10) is within peptide GSPAIFQSSMTKILE (HC088) that was recognized by VID409, 1/12 vaccinated subjects. IL10 restriction was not determined.

References

Displaying record number 61819

Download this epitope record as JSON.

HXB2 Location	Pol(322-336) RT(167-181) DNA(3048..3092)	Pol Epitope Map
Author Location	RT(167-181)
Epitope	`ILEPFRAQNPEIVIY`	Epitope Alignment
Epitope Name	HC091
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID410: A30:02, B18:01, B57:03, C07:01, C*18:01
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Peptide HC091, ILEPFRAQNPEIVIY, was recognized by VID410, 1/12 vaccinated subjects. It contains 3 truncated peptides eliciting CTL responses as seen by ICS: FRAQNPEIVIY (FY11), AQNPEIVIY (AY9), and AQNPEIVIY (RY10) restriction unknown.

References

Displaying record number 61820

Download this epitope record as JSON.

HXB2 Location	Pol(326-336) RT(171-181) DNA(3060..3092)	Pol Epitope Map
Author Location
Epitope	`FRAQNPEIVIY`	Epitope Alignment
Epitope Name	FY11
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID410: A30:02, B18:01, B57:03, C07:01, C*18:01
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope FRAQNPEIVIY (FY11) is within peptide ILEPFRAQNPEIVIY (HC091) that was recognized by VID410, 1/12 vaccinated subjects. This epitope has not been reported before, restriction unknown.

References

Displaying record number 61823

Download this epitope record as JSON.

HXB2 Location	Pol(326-342) RT(171-187) DNA(3060..3110)	Pol Epitope Map
Author Location	Pol(167-181)
Epitope	`FRAQNPEIVIYQYMDKK`	Epitope Alignment
Epitope Name	HC092
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID410: A30:02, B18:01, B57:03, C07:01, C*18:01
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Peptide HC092, FRAQNPEIVIYQYMD(KK), was recognized by VID410, 1/12 vaccinated subjects, and mapping identified the B*1801-restricted A-list candidates EIVIYQYMD (ED9) and PEIVIYQYM (PM9) as novel epitopes. Previously published A-list epitope NPEIVIYQY (NY9) is also present within this peptide, but was not confirmed as eliciting response in this case.

References

Displaying record number 61821

Download this epitope record as JSON.

HXB2 Location	Pol(327-336) RT(172-181) DNA(3063..3092)	Pol Epitope Map
Author Location
Epitope	`RAQNPEIVIY`	Epitope Alignment
Epitope Name	RY10
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID410: A30:02, B18:01, B57:03, C07:01, C*18:01
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope RAQNPEIVIY (RY10) is within peptide ILEPFRAQNPEIVIY (HC091) that was recognized by VID410, 1/12 vaccinated subjects. This epitope has not been reported before, restriction unknown.

References

Displaying record number 61822

Download this epitope record as JSON.

HXB2 Location	Pol(328-336) RT(173-181) DNA(3066..3092)	Pol Epitope Map
Author Location
Epitope	`AQNPEIVIY`	Epitope Alignment
Epitope Name	AY9
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID410: A30:02, B18:01, B57:03, C07:01, C*18:01
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope AQNPEIVIY (AY9) is within peptide ILEPFRAQNPEIVIY (HC091) that was recognized by VID410, 1/12 vaccinated subjects. This epitope is reported to be restricted by HLA-A*3002 and variant kQNPEIVIY is in the Los Alamos HIV Immunology database A-list.

References

Displaying record number 61824

Download this epitope record as JSON.

HXB2 Location	Pol(329-344) RT(174-189) DNA(3069..3116)	Pol Epitope Map
Author Location	Pol(174-189)
Epitope	`KNPEIVIYQYMDDLYV`	Epitope Alignment
Epitope Name	HC093
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID415: A02:01, A03:01, B07:02, B44:02, C07:02, DQB103:01, DQB106:02, DRB111:04, DRB115:01, DRB3, DRB5; VID410: A30:02, B18:01, B57:03, C07:01, C18:01; VID411: A02:01, B08:01, B51:01, C03:03, C07:01, DQB102, DQB103:03, DRB103:01, DRB109:01, DRB3, DRB5; VID416: A02:01, B08:01, B44:02, C05:01, C07:01; VID418: A02:01, A24:02, B07:02, B27:05, C01:02, C07:02, DQB103:01, DQB103:03, DRB104:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Peptide HC093, (K)NPEIVIYQYMDDLYV, was recognized by VID410, 1/12 vaccinated subjects, and mapping identified the B*1801-restricted A-list candidates EIVIYQYMD (ED9) and PEIVIYQYM (PM9) as novel epitopes. Previously published A-list epitope NPEIVIYQY (NY9) is also present within this peptide, but was not confirmed as eliciting response in this case.
HC093 was also recognized by VIDs 411, 415, 416, 418, 4/12 more vaccinated subjects, and mapping identified the A*0201-restricted novel epitope A-list candidate VIYQYMDDLYV (VV11) as well as YQYMDDLYV (YV9) as epitopes eliciting response in VID416. Other overlapping epitopes not yet confirmed were IYQYMDDLYV (IV10) and QYMDDLYV (QV8).
VID417 had a different pattern of overlapping epitopes that were not investigated.

References

Displaying record number 61825

Download this epitope record as JSON.

HXB2 Location	Pol(331-339) RT(176-184) DNA(3075..3101)	Pol Epitope Map
Author Location
Epitope	`PEIVIYQYM`	Epitope Alignment
Epitope Name	PM9
Species (MHC/HLA)	human(B*18:01)
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID410: A30:02, B18:01, B57:03, C07:01, C*18:01
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, optimal epitope, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope PEIVIYQYM (PM9) is within peptides FRAQNPEIVIYQYMDKK (HC092) and KNPEIVIYQYMDDLYV (HC093) that was recognized by VID410, 1/12 vaccinated subjects. PM9 is an HLA-B*1801 restricted A-list candidate epitope for the Los Alamos HIV Immunology database .

References

Displaying record number 61826

Download this epitope record as JSON.

HXB2 Location	Pol(332-340) RT(177-185) DNA(3078..3104)	Pol Epitope Map
Author Location
Epitope	`EIVIYQYMD`	Epitope Alignment
Epitope Name	ED9
Species (MHC/HLA)	human(B*18:01)
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID410: A30:02, B18:01, B57:03, C07:01, C*18:01
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, optimal epitope, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope EIVIYQYMD (ED9) is within peptides FRAQNPEIVIYQYMDKK (HC092) and KNPEIVIYQYMDDLYV (HC093) that was recognized by VID410, 1/12 vaccinated subjects. ED9 is an HLA-B*1801 restricted A-list candidate epitope for the Los Alamos HIV Immunology database .

References

Displaying record number 61827

Download this epitope record as JSON.

HXB2 Location	Pol(334-344) RT(179-189) DNA(3084..3116)	Pol Epitope Map
Author Location
Epitope	`VIYQYMDDLYV`	Epitope Alignment
Epitope Name	VV11
Species (MHC/HLA)	human(A*02:01)
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID416: A02:01, B08:01, B44:02, C05:01, C*07:01
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope VIYQYMDDLYV (VV11) is within peptide KNPEIVIYQYMDDLYV (HC093) that was recognized by VID416, 1/12 vaccinated subjects. VV11 is an HLA-A*0201 restricted A-list candidate epitope for the Los Alamos HIV Immunology database .

References

Displaying record number 61828

Download this epitope record as JSON.

HXB2 Location	Pol(336-344) RT(181-189) DNA(3090..3116)	Pol Epitope Map
Author Location
Epitope	`YQYMDDLYV`	Epitope Alignment
Epitope Name	YV9
Species (MHC/HLA)	human(A*02:01)
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID416: A02:01, B08:01, B44:02, C05:01, C*07:01
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, optimal epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope YQYMDDLYV (YV9) is within peptide KNPEIVIYQYMDDLYV (HC093) that was recognized by VID416, 1/12 vaccinated subjects. YV9 is a published A-list epitope of the Los Alamos HIV Immunology database.

References

Displaying record number 61830

Download this epitope record as JSON.

HXB2 Location	Pol(337-344) RT(182-189) DNA(3093..3116)	Pol Epitope Map
Author Location
Epitope	`QYMDDLYV`	Epitope Alignment
Epitope Name	QV8
Species (MHC/HLA)	human(A*02:01)
Immunogen	HIV-1 infection, vaccine
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope QYMDDLYV (QV8) is within peptide KNPEIVIYQYMDDLYV (HC093) that was recognized by VID418, 1/12 vaccinated subjects. QV8 is an HLA-A*0201-restricted novel epitope.

References

Displaying record number 61836

Download this epitope record as JSON.

HXB2 Location	Pol(705-714) RT(550-559) DNA(4197..4226)	Pol Epitope Map
Author Location
Epitope	`KLVSQGIRKV`	Epitope Alignment
Epitope Name	KV10
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope AKEIVASCD (AD9) is within peptide DKAQAKEIVASCDKC (HC139) that was recognized by VID 404, 1/12 vaccinated subjects. AD9 is novel, but of unknown restriction.

References

Displaying record number 61837

Download this epitope record as JSON.

HXB2 Location	Pol(705-716) RT(550)-Integrase(1) DNA(4197..4232)	Pol Epitope Map
Author Location
Epitope	`KLVSQGIRKVLF`	Epitope Alignment
Epitope Name	KF12
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope KLVSQGIRKVLF (KF12) is within peptide KLVSQGIRKVLFLDG (HC135) that was recognized by VIDs 416 and 418, 2/12 vaccinated subjects. KF12 is a novel epitope of unknown restriction.

References

Displaying record number 61835

Download this epitope record as JSON.

HXB2 Location	Pol(705-719) RT(550)-Integrase(4) DNA(4197..4241)	Pol Epitope Map
Author Location	Pol(705-719)
Epitope	`KLVSQGIRKVLFLDG`	Epitope Alignment
Epitope Name	HC135
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Peptide HC135, KLVSQGIRKVLFLDG, was recognized by VIDs 416 and 418, 2/12 vaccinated subjects. It contains the novel epitopes HLA-A*0201-restricted epitope KLVSQGIRKV (KV10), record #61836, and KLVSQGIRKVLF (KF12), record #61837, of unknown restriction.

References

Displaying record number 61838

Download this epitope record as JSON.

HXB2 Location	Pol(744-758) Integrase(29-43) DNA(4314..4358)	Pol Epitope Map
Author Location	Pol(744-758)
Epitope	`DKAQAKEIVASCDKC`	Epitope Alignment
Epitope Name	HC139
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID404: A68:01, B44:02, B51:01, C07:04, C14:02, DQB106:02, DQB106:05, DRB113:01, DRB1*13:02, DRB3
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Peptide HC139, DKAQAKEIVASCDKC, was recognized by VID404, 1/12 vaccinated subjects. It contains 3 novel truncated peptides eliciting CTL responses as seen by ICS, within a larger subpeptide, AC11, AKEIVASCDKC: EIVASCDK (EK8), and KEIVASCDKC (KC10); as well as AKEIVASCD (AD9) all of unknown restriction.

References

Displaying record number 61839

Download this epitope record as JSON.

HXB2 Location	Pol(748-756) Integrase(33-41) DNA(4326..4352)	Pol Epitope Map
Author Location
Epitope	`AKEIVASCD`	Epitope Alignment
Epitope Name	AD9
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID404: A68:01, B44:02, B51:01, C07:04, C14:02, DQB106:02, DQB106:05, DRB113:01, DRB1*13:02, DRB3
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope AKEIVASCD (AD9) is within peptide DKAQAKEIVASCDKC (HC139) that was recognized by VID 404, 1/12 vaccinated subjects. AD9 is novel, but of unknown restriction.

References

Displaying record number 61840

Download this epitope record as JSON.

HXB2 Location	Pol(748-758) Integrase(33-43) DNA(4326..4358)	Pol Epitope Map
Author Location
Epitope	`AKEIVASCDKC`	Epitope Alignment
Epitope Name	AC11
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID404: A68:01, B44:02, B51:01, C07:04, C14:02, DQB106:02, DQB106:05, DRB113:01, DRB1*13:02, DRB3
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Novel peptide AKEIVASCDKC (AC11) is within peptide DKAQAKEIVASCDKC (HC139) that was recognized by VID 404, 1/12 vaccinated subjects. AC11 is novel, but of unknown restriction, though two epitopes are predicted within it to be AKEIVASCDKC (EK8) and AKEIVASCDKC (KC10) predicted to be restricted by HLA-A*67801 and HLA-B*4402 respectively.

References

Displaying record number 61841

Download this epitope record as JSON.

HXB2 Location	Pol(767-782) Integrase(52-67) DNA(4383..4430)	Pol Epitope Map
Author Location	Pol(767-782)
Epitope	`GQVDCSPGIWQLDCTH`	Epitope Alignment
Epitope Name	HC145
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID404: A68:01, B44:02, B51:01, C07:04, C14:02, DQB106:02, DQB106:05, DRB113:01, DRB1*13:02, DRB3
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Peptide HC145, GQVDCSPGIWQLDCTH, was recognized by VID404, 1/12 vaccinated subjects. It contains a novel, optimal truncated epitope GIWQLDCTH (GH9) eliciting CTL responses as seen by ICS. It is of unknown restriction.

References

Displaying record number 61842

Download this epitope record as JSON.

HXB2 Location	Pol(774-782) Integrase(59-67) DNA(4404..4430)	Pol Epitope Map
Author Location
Epitope	`GIWQLDCTH`	Epitope Alignment
Epitope Name	GH9
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID404: A68:01, B44:02, B51:01, C07:04, C14:02, DQB106:02, DQB106:05, DRB113:01, DRB1*13:02, DRB3
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope GIWQLDCTH (GH9) is within peptide GQVDCSPGIWQLDCTH (HC145) that was recognized by VID404, 1/12 vaccinated subjects. GH9 is of unknown restrtiction but is a novel, optimal epitope.

References

Displaying record number 61850

Download this epitope record as JSON.

HXB2 Location	Pol(891-905) Integrase(176-190) DNA(4755..4799)	Pol Epitope Map
Author Location	Integrase(176-191)
Epitope	`VQMAVFIHNFKRKGG`	Epitope Alignment
Epitope Name	HC164
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID410: A30:02, B18:01, B57:03, C07:01, C18:01; VID404: A68:01, B44:02, B51:01, C07:04, C14:02, DQB106:02, DQB106:05, DRB113:01, DRB113:02, DRB3
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Peptide HC164, VQMAVFIHNFKRKGG, was recognized by VIDs 404 and 410, 2/12 vaccinated subjects. It contains epitope IHNFKRKGG (IG9) of unknown restriction which is a novel epitope.

References

Displaying record number 61844

Download this epitope record as JSON.

HXB2 Location	Pol(897-905) Integrase(182-190) DNA(4773..4799)	Pol Epitope Map
Author Location
Epitope	`IHNFKRKGG`	Epitope Alignment
Epitope Name	IG9
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID410: A30:02, B18:01, B57:03, C07:01, C18:01; VID404: A68:01, B44:02, B51:01, C07:04, C14:02, DQB106:02, DQB106:05, DRB113:01, DRB113:02, DRB3
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope IHNFKRKGG (IG9) is within peptide VQMAVFIHNFKRKGGI (HC164) that was recognized by VIDs 404 and 410, 2/12 vaccinated subjects. IG9 is of unknown restrtiction but is a novel epitope.

References

Displaying record number 61848

Download this epitope record as JSON.

HXB2 Location	Pol(974-981) Integrase(259-266) DNA(5004..5027)	Pol Epitope Map
Author Location
Epitope	`VVPRRKAK`	Epitope Alignment
Epitope Name	VK8
Species (MHC/HLA)	human(B*08:01)
Immunogen	HIV-1 infection, vaccine
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope VVPRRKAK (VK8) is within peptide VVPRRKAKIIRDYGK (HC176). VK8 is an HLA-B*0801-restricted epitope which elicits a response.

References

Displaying record number 61845

Download this epitope record as JSON.

HXB2 Location	Pol(974-983) Integrase(259-268) DNA(5004..5033)	Pol Epitope Map
Author Location
Epitope	`VVPRRKAKII`	Epitope Alignment
Epitope Name	VI10
Species (MHC/HLA)	human(B*08:01)
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID413: A01:01, A03:01, B08:01, B44:02, C05:01, C07:01, DQB102, DQB103:01, DRB103:01, DRB111:01, DRB3
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope VVPRRKAKII (VI10) is within peptide VVPRRKAKIIRDYGK (HC176). VI10 is an HLA-B*0801-restricted novel epitope which is a candidate for the Los Alamos Immunology database A-list.

References

Displaying record number 61843

Download this epitope record as JSON.

HXB2 Location	Pol(974-988) Integrase(259-273) DNA(5004..5048)	Pol Epitope Map
Author Location	Integrase(259-273)
Epitope	`VVPRRKAKIIRDYGK`	Epitope Alignment
Epitope Name	HC176
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID413: A01:01, A03:01, B08:01, B44:02, C05:01, C07:01, DQB102, DQB103:01, DRB103:01, DRB111:01, DRB3
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Peptide HC176, VVPRRKAKIIRDYGK, was recognized by VID 413, 1/12 vaccinated subjects. It contains 3 truncated peptides VVPRRKAKII (VI10), RKAKIIRDYGK (RK11) and KIIRDYGK (KK8) eliciting CTL responses as seen by ICS. All were restricted through HLA-B*0801. Epitopes VPRRKAKI (VI8) and VVPRRKAK (VK8) were also able to induce CTL responses and were restricted by B*0801 too.

References

Displaying record number 61849

Download this epitope record as JSON.

HXB2 Location	Pol(975-982) Integrase(260-267) DNA(5007..5030)	Pol Epitope Map
Author Location
Epitope	`VPRRKAKI`	Epitope Alignment
Epitope Name	VI8
Species (MHC/HLA)	human(B*08:01)
Immunogen	HIV-1 infection, vaccine
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope VPRRKAKI (VI8) is within peptide VVPRRKAKIIRDYGK (HC176). VI8 is an HLA-B*0801-restricted epitope which elicits a response.

References

Displaying record number 61846

Download this epitope record as JSON.

HXB2 Location	Pol(978-988) Integrase(263-273) DNA(5016..5048)	Pol Epitope Map
Author Location
Epitope	`RKAKIIRDYGK`	Epitope Alignment
Epitope Name	RK11
Species (MHC/HLA)	human(B*08:01)
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID413: A01:01, A03:01, B08:01, B44:02, C05:01, C07:01, DQB102, DQB103:01, DRB103:01, DRB111:01, DRB3
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope RKAKIIRDYGK (RK11) is within peptide VVPRRKAKIIRDYGK (HC176). RK11 is an HLA-B*0801-restricted novel epitope which is a candidate for the Los Alamos Immunology database A-list.

References

Displaying record number 61847

Download this epitope record as JSON.

HXB2 Location	Pol(981-988) Integrase(266-273) DNA(5025..5048)	Pol Epitope Map
Author Location
Epitope	`KIIRDYGK`	Epitope Alignment
Epitope Name	KK8
Species (MHC/HLA)	human(B*08:01)
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID413: A01:01, A03:01, B08:01, B44:02, C05:01, C07:01, DQB102, DQB103:01, DRB103:01, DRB111:01, DRB3
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope KIIRDYGK (KK8) is within peptide VVPRRKAKIIRDYGK (HC176). KK8 is an HLA-B*0801-restricted novel epitope which is a candidate for the Los Alamos Immunology database A-list.

References

Displaying record number 61829

Download this epitope record as JSON.

HXB2 Location	Vif(11-26) DNA(5071..5118)	Vif Epitope Map
Author Location	Vif(11-26)
Epitope	`KQVDRMRIRTWKSLVK`	Epitope Alignment
Epitope Name	HC102
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID403: A01:01, A30:01, B13:02, B39:01, C06:02, C07:01, DQB102, DQB105, DRB107:01, DRB116:01, DRB4, DRB5
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Peptide HC102, (K)QVDRMRIRTWKSLVK, was recognized by VID403, 1/12 vaccinated subjects. It contains 3 truncated peptides eliciting CTL responses as seen by ICS, within a larger subpeptide, MK11, MRIRTWKSLVK: RIRTWKSLVK (RK10), record #61831, MRIRTWKSL (ML9) record #61668, and IRTWKSLVK (IK9) record #61760 restricted by HLA-A*3001. ML9 was not confirmed to be an epitope and another sequence, RTWKSLVK (RK9) which though not tested, has been seen in other HIVconsv vaccine-infected cells.

References

Displaying record number 61833

Download this epitope record as JSON.

HXB2 Location	Vif(16-30) DNA(5086..5130)	Vif Epitope Map
Author Location	Vif(16-30)
Epitope	`MRIRTWKSLVKHHLT`	Epitope Alignment
Epitope Name	HC103
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID418: A02:01, A24:02, B07:02, B27:05, C01:02, C07:02, DQB103:01, DQB103:03, DRB104:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Peptide HC103, MRIRTWKSLVKHHLT, was recognized by VID418, 1/12 vaccinated subjects. It contains the optimal, novel HLA-B*2705-restricted epitope IRTWKSLVKH (IH10).

References

Displaying record number 61831

Download this epitope record as JSON.

HXB2 Location	Vif(17-26) DNA(5089..5118)	Vif Epitope Map
Author Location
Epitope	`RIRTWKSLVK`	Epitope Alignment
Epitope Name	RK10
Species (MHC/HLA)	human(A*30:01)
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID403: A01:01, A30:01, B13:02, B39:01, C06:02, C07:01, DQB102, DQB105, DRB107:01, DRB116:01, DRB4, DRB5
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope RIRTWKSLVK (RK10) is within peptide KQVDRMRIRTWKSLVK (HC102) that was recognized by VID403, 1/12 vaccinated subjects. RK10 is an HLA-A*3001-restricted novel epitope which is a candidate for the Los Alamos Immunology database A-list, it already exists as an A-list epitope when restricted by A*0301.

References

Displaying record number 61832

Download this epitope record as JSON.

HXB2 Location	Vif(18-26) DNA(5092..5118)	Vif Epitope Map
Author Location
Epitope	`IRTWKSLVK`	Epitope Alignment
Epitope Name	IK9
Species (MHC/HLA)	human(A*30:01)
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID403: A01:01, A30:01, B13:02, B39:01, C06:02, C07:01, DQB102, DQB105, DRB107:01, DRB116:01, DRB4, DRB5
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope IRTWKSLVK (IK9) is within peptide KQVDRMRIRTWKSLVK (HC102) that was recognized by VID403, 1/12 vaccinated subjects. IK9 is an HLA-A*3001-restricted novel epitope which is a candidate for the Los Alamos Immunology database A-list.

References

Displaying record number 61834

Download this epitope record as JSON.

HXB2 Location	Vif(18-27) DNA(5092..5121)	Vif Epitope Map
Author Location
Epitope	`IRTWKSLVKH`	Epitope Alignment
Epitope Name	IH10
Species (MHC/HLA)	human(B*27:05)
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	VID418: A02:01, A24:02, B07:02, B27:05, C01:02, C07:02, DQB103:01, DQB103:03, DRB104:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, novel epitope

Notes

Since CTL response in natural HIV-1 infections is mostly against variable but immunodominant epitopes, lymphocytes from 12 vaccine(HIVconsv)-exposed subjects of the HIV-CORE 002 study were used to determine and define 14 less variable but typically subdominant, optimal novel epitopes.
Epitope IRTWKSLVKH (IH10) is within peptide MRIRTWKSLVKHHLT (HC103) that was recognized by VID418, 1/12 vaccinated subjects. IH10 is an HLA-B*2705-restricted novel, optimal epitope which is a candidate for the Los Alamos Immunology database A-list.